{"extracted_data":{"results":{"group_difference":"no difference was observed between groups (p=0.51)","pembrolizumab alone (IO-mono)":{"os_12_month":"66.1%","median_rw_pfs":"10.6 months","median_os":"not reached"},"pembrolizumab in combination with platinum-based chemotherapy (CT-IO)":{"median_os":"not reached","os_12_month":"70.2%","median_rw_pfs":"11.3 months"}},"study_name":"Study from Pons-Tostivint 2023.pdf","file_name":"Pons-Tostivint 2023.pdf","treatment_regimens":["pembrolizumab alone (IO-mono)","pembrolizumab in combination with platinum-based chemotherapy (CT-IO)"],"countries":["France"],"populations":[{"n":243,"stage, histology":"Stage III and IV, non-squamous and squamous NSCLC","pdl1_status":"PD-L1 ≥ 50%"},{"n":59,"stage, histology":"Stage IV, non-squamous NSCLC","pdl1_status":"PD-L1 ≥ 90%"},{"pdl1_status":"PD-L1 50-89%","n":82,"stage, histology":"Stage IV, non-squamous NSCLC"},{"stage, histology":"Locally advanced, non-squamous NSCLC","pdl1_status":"PD-L1 ≥ 50%","n":26},{"n":115,"stage, histology":"Metastatic, non-squamous NSCLC","pdl1_status":"PD-L1 ≥ 50%"}]},"status":"success","_timestamp":1.7426781902449348e+09,"_wandb":{"runtime":12},"_runtime":12.848991,"_step":0,"study_name":"Study from Pons-Tostivint 2023.pdf"}